Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AMNEAL PHARMACEUTICALS, INC.

(AMRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Amneal Pharmaceuticals Obtains FDA Approval for Difluprednate Ophthalmic Emulsion

11/19/2021 | 08:39am EST


ę MT Newswires 2021
All news about AMNEAL PHARMACEUTICALS, INC.
01/12Amneal Pharmaceuticals Seeks Tuck-In Acquisitions
CI
01/11AMNEAL PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Regulation F..
AQ
01/11Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full Year 2021
CI
01/06Amneal Acquires Saol Therapeutics' Baclofen Franchise
AQ
01/05Amneal Acquires Saol's Baclofen For $83.5 Million Plus Royalties
MT
01/05AMNEAL PHARMACEUTICALS : Acquires Saol Therapeutics' Baclofen Franchise - Form 8-K
PU
01/05AMNEAL PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Regulation FD D..
AQ
01/05Amneal Acquires Saol Therapeutics' Baclofen Franchise
BU
2021Amneal to Virtually Participate at the 40th Annual J.P. Morgan Healthcare Conference
BU
2021Amneal Receives Approval for Difluprednate Ophthalmic Emulsion
AQ
More news
Analyst Recommendations on AMNEAL PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 2 094 M - -
Net income 2021 59,7 M - -
Net Debt 2021 2 350 M - -
P/E ratio 2021 89,2x
Yield 2021 -
Capitalization 666 M 666 M -
EV / Sales 2021 1,44x
EV / Sales 2022 1,31x
Nbr of Employees 6 000
Free-Float -
Chart AMNEAL PHARMACEUTICALS, INC.
Duration : Period :
Amneal Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMNEAL PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 4,46 $
Average target price 7,20 $
Spread / Average Target 61,4%
EPS Revisions
Managers and Directors
Chintu Patel Co-Chief Executive Officer & Director
Chirag K. Patel President & Co-Chief Executive Officer & Director
Anastasios G. Konidaris Chief Financial Officer & Senior Vice President
Paul M. Meister Chairman
Andrew S. Boyer Executive Vice President-Commercial Operations
Sector and Competitors
1st jan.Capi. (M$)
AMNEAL PHARMACEUTICALS, INC.-6.89%666
JOHNSON & JOHNSON-3.40%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-11.98%220 356